Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ADVANCED ONCOTHERAPY PLC. We currently have 45 research reports from 4 professional analysts.
Frequency of research reports
Research reports on
ADVANCED ONCOTHERAPY PLC
ADVANCED ONCOTHERAPY PLC
03 Apr 17
After much heralding, MIFID II is finally beginning to have an impact on the business of investment research, though its true ramifications might take years to be seen. The role of analyst research is widely misunderstood. It is not all about the conclusion: the rating and price target. The real content of research is about what is discounted in the current share price and what assumptions would produce different outcomes.
Delivery of LIGHT
15 Mar 17
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on its Harley Street site expected to commence this month following preliminary assessment work. Meanwhile, individual modules for the LIGHT system are being integrated and tested in Geneva. At the March 2017 investor presentations, AVO provided a revised timeline for completion of the London Proton Therapy Centre, first patient treatments, and an update on its commercial and financial strategies.
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
Small Cap Breakfast
24 Feb 17
GBGI—Schedule One update from integrated provider of international benefits insurance. Raising £32m at 150p. Admission expected tomorrow. Anglo African Oil & Gas— Admission expected early March. Acquiring stake in producing near offshore field in the Republic of the Congo. Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb.
20 Feb 17
Steve Mnuchin, US Treasury Secretary, rather clouded Trump's revolutionary picture when speaking at his first press conference last week. Possibly he was under orders to leave key details for Trump himself to divulge at tomorrow's State of the Union Address or, just maybe, he is still confused as the rest of us. Whatever, in failing to provide any detail regarding the much anticipated corporate and personal tax reform packages championed during the Presidential campaign and, instead adopting the prudent view that the impact from the Republican's prospective fiscal policy will not be felt until 2018, initially unnerved the US markets on Friday. Investors were certainly left considering the giant injection of new spending to rebuild the country's tired infrastructure was going to take more time to deliver than currently expected although, more positively Mr Mnuchin did appear to be watering down the President's earlier attack on 'currency manipulator' China. As a result, the Dow Jones fell over 75 points during Friday's morning trade before the wall of money being liberated from global government bond markets flooded back in to ensure all three principal indices clawed back into the positive with the Industrial Average itself scaping a fractional gain, albeit sufficient for it to chalk up its 11th consecutive record closing. Asia by comparison was weaker across the board this morning, with Japan leading the decline as Nikkei sentiment again pivoted downward on modest Yen:US$ gains, dragging the Chinese indices with it while the commodity-rich ASX continued to nurse losses amongst its minerals plays. This week's primary macro focus will, of course, be on tomorrow's President's speech and to a lesser extent further comments anticipated from various Fed officials regarding prospective interest rate policy. No significant macro data is expected from the UK today, although the EU is due to publish a batch of statistics, ranging from M3 Money Supply, Services/Consumer sentiment and Industrial Confidence while the US, similarly, is expected to deliver January Durable Goods Orders and Pending Home Sales before FOMC member Robert Kaplan is scheduled to speak. UK corporates due to publish earnings or trading updates include Bunzl (BNZL.L), McColl's Retail Group (MCLS.L), Persimmon (PSN.L), Senior (SNR.L), Trinity Mirror (TNI.L) and Volex (VLX.L). London is seen drawing on the late enthusiasm than powered the US indices into the positive on Friday, with the FTSE-100 seen rising some 20 points in early trading. Investors will, however, be keen to learn more from the London Stock Exchange (LSE.L), given comments that emerged in the media late Sunday, suggesting that regulatory impositions, such as the sale of its Italian fixed income trading platform, were so overwhelming that the planned €29bn merger with Germany's Deutsche Börse was now at risk.
The Quest for Dividends
01 Feb 17
The Dow Jones Index has just breached the 20,000 mark, the first time in its 131- year history that it has done so, whilst the FTSE-100 Index has also been at record levels in recent weeks. The election of the controversial Donald Trump as the new US President, and more specifically the impact of his planned expansionist economic policies, have boosted stock markets, both in the US and in the UK.
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
Positive top-line results in first iclaprim phase III clinical trial (REVIVE-1)
18 Apr 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, announced positive results this morning in the first of its two iclaprim phase III clinical trials, REVIVE-1, comparing iclaprim to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Iclaprim, a next-generation antibiotic targeting an underutilised mechanism of action which causes rapid killing of bacteria, is being developed for the treatment of serious and life threatening bacterial infections. On the key primary endpoint in the study, early clinical response at 48-72 hours after drug treatment began, 80.9% of patients on iclaprim achieved a positive response compared to 81.0% of patients on vancomycin, well within the 10% non-inferiority margin required by the FDA. Iclaprim was also shown to be safe and well-tolerated compared to vancomycin. With these positive results from REVIVE-1 we have increased the probability of success for the iclaprim development program from 65% to 75% raising our risk-adjusted NPV for Motif Bio to almost £240m or 122p per share (previously £210m and 107p per share).
N+1 Singer - Sinclair Pharma - EBITDA upgrade for 2017, but lower TP due to warranty claim and costs
19 Apr 17
We have updated product-level forecasts and included the £10m SVB debt facility and £5m warranty claim settlement with Alliance Pharma in our forecasts. The 6.3% upgrade to our FY2017 sales estimate (from £46.0m to £48.9m) brings expected EBITDA profitability forward by one year (to FY2017 from FY2018). We remain positive on the ongoing rollout of Silhouette Instalift® in particular and retain our Buy recommendation. However, higher expected sales & marketing costs and the warranty claim weigh on our valuation: we downgrade our target price from 42p to 37p.
Positive REVIVE-1 Phase III study data
18 Apr 17
Motif Bio (MTFB) has announced positive top-line results from REVIVE-1, its global Phase III study comparing iclaprim to vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI). Iclaprim achieved the primary endpoint of non inferiority when compared to vancomycin, in both the early time point and test of cure endpoint. Iclaprim offers clinical advantages over existing hospital antibiotics that include the avoidance of renal toxicity, fixed dosage regimen and early response indications. With data from REVIVE-2 due out in H2 2017 we maintain our 125p price target and Buy recommendation.